leisure time -WSS

leisure time

author：entertainment 2025-09-27 09:45:08 - browse：39

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Grail faces three suits alleging harassment, retaliation

Wikipedia

WSS

Head of FDA's diagnostics center, who led through Covid, retires

Inaction leaves children at risk from dangerous chemotherapy drug

Printout prescription drug information shouldn’t go digital

Inaction leaves children at risk from dangerous chemotherapy drug

J&J expands global access to TB drug amid advocacy campaign

J&J expands global access to TB drug amid advocacy campaign

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Global childhood vaccinations edge closer to pre

Medicare proposal to cover medical devices draws a mixed reaction

Blood tests recalled over risk of missed heart attack diagnosis

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Argenx drug significantly slows progression of nerve disorder

Anesthesiologist group: stop taking Ozempic before surgery

Europe sees delivery challenges ahead on Alzheimer's therapies

After affirmative action ruling, medical educators look to 'holistic review'

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

leisure time

Europe sees delivery challenges ahead on Alzheimer's therapies

TikTok, Instagram influencers need more rules for drug ads

Argenx drug significantly slows progression of nerve disorder

Does aspartame cause cancer? What new WHO guidance says

To bolster infectious disease surveillance, genomics powerhouses team up

Grail faces three suits alleging harassment, retaliation

hotspot

explore

Wikipedia

hotspot